Section Arrow
REPL.NASDAQ
- Replimune Group
Quotes are at least 15-min delayed:2025/07/21 08:28 EDT
Pre Market
Last
 13.4
+1.31 (+10.84%)
Bid
13.19
Ask
13.46
High 14.99 
Low 12.5 
Volume 185465 
Regular Hours
Last
 12.09
-0.41 (-3.28%)
Day High 
12.78 
Prev. Close
12.5 
1-M High
13.19 
Volume 
3.35M 
Bid
13.19
Ask
13.46
Day Low
11.6201 
Open
12.63 
1-M Low
8.92 
Market Cap 
963.58M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 10.93 
20-SMA 10.17 
50-SMA 9.34 
52-W High 17 
52-W Low 6.44 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.07/-2.89
Enterprise Value
1.04B
Balance Sheet
Book Value Per Share
5.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.0101 -0.2699 -11.84%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 12.7603 -1.3147 -9.34%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0553 +0.0076 +15.93%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.17 +0.33 +5.65%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.25 +0.33 +5.57%
Quotes are at least 15-min delayed:2025/07/21 08:28 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.